Interim Phase 2b data in December 2026 is the next major catalyst. Monitor for top-line results on symptoms, histology, and safety in the first 60 patients at 6 months.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals announced it reached the enrollment target of 120 patients in the Phase 2b placebo-controlled portion of the RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis. The company confirmed the sample size does not need adjustment and reported no treatment-related serious adverse events across over 3,000 injections. Interim Phase 2b data is expected in December 2026.
Key Facts
- Enrolled 120th patient in Phase 2b placebo-controlled portion on October 12, 2026.
- Interim analysis of Phase 2b data on track for December 2026.
- Over 3,000 injections administered with no treatment-related serious adverse events (SAEs).
- Sample size re-estimation confirmed no adjustment needed.
- Phase 2b evaluating 120mg and 160mg doses vs vehicle control in 1:1:1 randomization.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech with no approved products.
Risk Factors
- Phase 2b interim data may fail to show statistical significance on primary endpoints.
- Clinical-stage company with no approved products and no revenue; requires additional financing.
- Prior restatement of financial statements noted as a risk factor.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006648 |
| Document: f6k_101526.htm | 0001171843-26-006648 |
| Document: 0001171843-26-006648-index-headers.html | 0001171843-26-006648 |
| Document: 0001171843-26-006648-index.html | 0001171843-26-006648 |
| Document: 0001171843-26-006648.txt | 0001171843-26-006648 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers